Skip to main content
Main navigation - Mobile
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
SCOTUS rebuffs Gilead, Merck appeals in high-profile battles
Tuesday, January 8, 2019
Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.
DOJ moves to kill its Gilead false claims case
Monday, December 3, 2018
The Justice Department will no longer pursue a whistleblower case against Gilead for using an unapproved API in some HIV drugs.
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead
Tuesday, August 7, 2018
It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.
Gilead shelved safer HIV drugs to shield older drugs: lawsuit
Wednesday, May 9, 2018
Patients allege that Gilead held off on developing its better HIV candidates until older drugs neared the end of their patent lives.
Besieged Teva launches exclusive generic of Gilead's Viread
Friday, December 15, 2017
Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread.
FiercePharmaAsia—Gilead, Biocon and AstraZeneca
Friday, July 14, 2017
A whistleblower suit against Gilead is revived, Biocon and Mylan's Herceptin biosim is delayed, and AZ is upping production to meet demands in China.
Gilead faces new heat in HIV drug whistleblower suit
Monday, July 10, 2017
Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.
Under a previous patent settlement with Gilead Sciences, Teva Pharmaceutical Industries will be able to launch a generic version of hepatitis B and HIV antiviral Viread late this year.